UK Cancer Biomarker Market Growth, Size, Share and Forecast 2019-2025

UK cancer biomarker market is expected to grow at a CAGR of around 11.7% during the forecast period. The major factor that are increasing the market are high prevalence of cancer in the region, well-developed healthcare infrastructure and presence of major market player in the nation. Additionally, as the country have developed economy, per capita healthcare investment from government and public is higher than other developing nation and hence significant research can be observed in the near future.

A full report of UK Cancer Biomarker Market is available at  https://www.omrglobal.com/industry-reports/uk-cancer-biomarker-market

The healthcare expenditure of the UK is more than $25,000 million as compared to Germany and France. This is one of the major factors that tends to rise the UK cancer biomarker market. AS per OECD, the prevalence of cancer in the UK is  approx. 225 per 100,000 people in 2011 which is estimated to reduce only to 214 per 100,000 people in 2017. The incidences of cancer patients in the UK has been very frequent previously.

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/uk-cancer-biomarker-market

The increasing integration of healthcare with technology is augmenting the UK cancer biomarker market. There are various procedures that are being uniquely available at UK treatment centers. For instance, the Clatter Bridge Cancer Centre is one of the first two hospitals in the UK to offer dose painting radiotherapy to patients. The technique is suitable for patients with a higher density of cancer cells, which have not spread from the prostate gland. This applies to 30- 50% of all prostate cancer cases. While an equal amount of radiation is delivered by the standard radiotherapy on prostate, in dose painting radiotherapy, MRI scans or PET CT scans first identify areas of the prostate which is more affected.

Further, during the year 2016/2017 the Cancer Research UK supported the research based on cancer worth $490.22 million. On the lung cancer research $55.11 million was spent whereas an amount of $44.06 million was spent in the research of colon and rectal cancer. For, breast cancer $ 41.65 million was spent on the research. The funding in the research is expected to motivate the UK market of cancer biomarker. Thus, such contributions by the government organizations is expected to further drive the UK cancer biomarker market.

UK Cancer Biomarker Market- Segmentation

By Biomarker Type

• Genetic Biomarker
• Protein Biomarker

By Cancer Type

• Lung Cancer
• Prostate Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Other

By Applications

• Drug Discovery and Development
• Diagnosis
• Risk Assessment
• Prognostics

By Profiling Technology

• Omics Technology
• Immunoassays
• Cytogenetics
• Bioinformatics

Visit for Global Cancer Biomarker Market Report at:  https://www.omrglobal.com/industry-reports/cancer-biomarkers-market

Company Profiles

• Abbott laboratories Inc.
• Astellas Pharma Inc.
• Becton, Dickson and Co.
• Bio-Rad Laboratories, Inc.
• Danaher Corp.
• F. Hoffmann-La Roche Ltd.
• Merck and Co., Inc.
• Novartis AG
• Pfizer Inc.
• QIAGEN GmbH
• Thermo Fisher Scientific Inc.

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +1 646-755-7667, +91 7803040404